Atea Pharmaceuticals

Concentra finds latest acquisition attempt harder to swallow as Atea rejects 'undervalued' offer
Concentra finds latest acquisition attempt harder to swallow as Atea rejects 'undervalued' offer
Fierce Biotech
Concerta Biosciences
M&A
Atea Pharmaceuticals
Flag link:
Concentra rebounds from Jounce buy with a shot at COVID-19-focused Atea
Concentra rebounds from Jounce buy with a shot at COVID-19-focused Atea
Fierce Biotech
Concerta Biosciences
Atea Pharmaceuticals
M&A
COVID-19
Flag link:
Atea dumps dengue drug as 'unevaluable' endpoint causes timelines, forecast costs to spiral
Atea dumps dengue drug as 'unevaluable' endpoint causes timelines, forecast costs to spiral
Fierce Biotech
Atea Pharmaceuticals
dengue
clinical trials
AT-752
Flag link:
Big Pharma has skirted long Covid, but a pipeline of small biotechs are testing treatments for lingering symptoms
Big Pharma has skirted long Covid, but a pipeline of small biotechs are testing treatments for lingering symptoms
Endpoints
COVID-19
Long COVID
GSK
Vir Biotechnology
Humanigen
Pfizer
Roche
Atea Pharmaceuticals
Flag link:
Atea sticks it out with failed COVID-19 antiviral but also raids Merck's store room for hepatitis C drug
Atea sticks it out with failed COVID-19 antiviral but also raids Merck's store room for hepatitis C drug
Fierce Biotech
Atea Pharmaceuticals
antivirals
COVID-19
Merck
bemnifosbuvir.
Flag link:
As Merck and Pfizer predict incoming billions from their COVID drugs, Roche culls pandemic ties with Atea
As Merck and Pfizer predict incoming billions from their COVID drugs, Roche culls pandemic ties with Atea
Fierce Biotech
Roche
Merck
Pfizer
Atea Pharmaceuticals
COVID-19
Flag link:
Atea’s antiviral pill fails to clear Covid-19, forcing a re-think
Atea’s antiviral pill fails to clear Covid-19, forcing a re-think
Stat
Atea Pharmaceuticals
COVID-19
antivirals
clinical trials
Roche
AT-527
Flag link:
Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?
Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?
Motley Fool
COVID-19
Merck
Ridgeback Therapeutics
Roche
Atea Pharmaceuticals
AT-527
antivirals
Flag link:
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
Motley Fool
Pfizer
M&A
Blueprint Medicines
Aurinia Pharmaceuticals
Atea Pharmaceuticals
Flag link:
Scientists work toward an elusive dream: a simple pill to treat Covid-19
Scientists work toward an elusive dream: a simple pill to treat Covid-19
Stat
COVID-19
drug development
Merck
Ridgeback Biotherapeutics
molnupiravir
Pfizer
Atea Pharmaceuticals
Flag link:
Atea, riding interest in COVID-19 drugs, pulls off one of 2020's top biotech IPOs
Atea, riding interest in COVID-19 drugs, pulls off one of 2020's top biotech IPOs
BioPharma Dive
Atea Pharmaceuticals
COVID-19
IPOs
small molecule drugs
Flag link:
Roche joins the COVID-19 antiviral drug race, betting $350M on a startup
Roche joins the COVID-19 antiviral drug race, betting $350M on a startup
BioPharma Dive
Roche
antivirals
Atea Pharmaceuticals
COVID-19
AT-527
Flag link:
Atea raises $215M to support midphase COVID-19 antiviral trial
Atea raises $215M to support midphase COVID-19 antiviral trial
Fierce Biotech
Atea Pharmaceuticals
clinical trials
COVID-19
antivirals
AT-527
Flag link: